GlassScriptPhysician profile
Richard Lewkowicz
NPI 1134319015
$8,966.60
in general payments reported to CMS, 2019-2025
35 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,040 · 2020: $1,073 · 2021: $812 · 2022: $1,018 · 2023: $199 · 2024: $527 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,210.76 | 2019-2025 | Biktarvy, Veklury |
| Lundbeck LLC | $624.99 | 2021-2024 | Vyepti |
| Mdd US Operations, LLC | $532.70 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $516.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $505.69 | 2019-2022 | |
| Novo Nordisk INC | $491.52 | 2019-2020 | |
| Allergan, INC. | $463.73 | 2019-2020 | |
| Acorda Therapeutics, INC | $379.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.01 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $367.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $362.91 | 2019-2022 | |
| Abbvie INC. | $325.36 | 2021-2022 | |
| Abbott Laboratories | $244.66 | 2022 | |
| Lilly USA, LLC | $192.57 | 2020 | |
| Astellas Pharma US INC | $169.07 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $154.84 | 2022 | |
| Mallinckrodt Hospital Products INC. | $141.43 | 2025 | Terlivaz |
| Ironshore Pharmaceuticals INC. | $127.00 | 2019 | |
| Amgen INC. | $125.00 | 2021 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Viiv Healthcare Company | $125.00 | 2019 | |
| Harmony Biosciences LLC | $125.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2019 | |
| Ucb, INC. | $124.50 | 2019 | |
| Nestle Healthcare Nutrition INC. | $122.43 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $121.59 | 2022 | |
| Eisai INC. | $119.92 | 2021 | |
| Pfizer INC. | $119.04 | 2019 | |
| Radius Health, INC. | $117.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $116.66 | 2019 | |
| Kyowa Kirin, INC. | $91.66 | 2019 | |
| Corcept Therapeutics | $76.11 | 2023 | Korlym |
| Janssen Pharmaceuticals, INC | $64.47 | 2019 | |
| Intra-Sana Laboratories | $50.00 | 2024 | Reltone 400 Mg, Reltone 200 Mg |
| Exact Sciences Corporation | $31.57 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lewkowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.